Alpine Immune Sciences
Seattle, US · Founded 2014 · Delaware corporation · 29 employees on LinkedIn · 8 known investors
Find your way into Alpine Immune Sciences
409 people in our graph share verified history with the Alpine Immune Sciences team — schools, employers, funds. One of them is your warm intro.
Dana Settleunlockedknows Ryan Swanson · together at University of Washington (overlapped)
knows the team · via Imperial College London
×5knows the team · via Amgen
×2knows the team · via University of Leicester
×3knows the team · via Western Washington University
Founders & leadership
Alpine Immune Sciences was founded in 2014 by Mitchell Gold.
MG
Mitchell GoldinCo-founder Executive Chairman and CEO2015–2024Venture Partner at Frazier Life Sciences
MK
Michael KornackerinCo-founder and VP Protein Engineering2015–2017Michael Kornacker is co-founder and executive officer of Alpine Immune Sciences, developing clinical-stage biopharmaceuticals. He spent two decades at Bristol-Myers Squibb and Amgen working on protein engineering and directed evolution for drug development, and holds multiple patents and publications in the field.
RS
Ryan SwansoninCo-Founder, Vice President Immunology2015–2019Ryan Swanson has over 25 years of experience in biologic therapeutics development, including discovery research roles at both large pharmaceutical companies and startups, with expertise in protein engineering and computational drug design.
DM
David MillerinDirector of Corporate Affairs2015–2019David Miller is an executive officer and director at Alpine Immune Sciences with over 25 years of experience in corporate strategy and business communications across multiple company stages, from early-stage ventures to public offerings, including two exits exceeding $1 billion and two IPOs. He has specialized in technology and biotechnology sector analysis and investor relations.
JP
James Paul RickeySenior Vice President and Chief Financial Officer
MJ
Mark James LittonPresident and Chief Operating Officer
TS
Tom SokolowskiExecutive
JV
Jay VenkatesanNamed on SEC filing
PT
CP
RC
Robert ConwayNamed on SEC filing
PS
Investors · 8
Decheng CapitalMenlo Park
Frazier Life SciencesPalo Altovia James N. Topper · led
Biotechnology Value Fundreported · 2 sourcesSan Francisco
OrbiMedreportedNew York · $1M – $75M
Also in the syndicate · 4
Avidity PartnersLogos CapitalOmega FundTCG X
Reported raises · per SEC filings
Form D private placements$234.9M disclosed across 7 rounds · 2014–2021
▶$91MraisedSep 2021 · 16 investors · BiotechnologyRule 506(b)
▶$91MraisedSep 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanford PengExecutive Officer
- Robert ConwayDirector
- Peter ThompsonDirector
- Jay VenkatesanDirector
- Zelanna GoldbergExecutive Officer
- Natasha HerndayDirector
- James Paul RickeyExecutive Officer
- Cui XiangminDirector
- Mitchell GoldExecutive Officer, Director
- James TopperDirector
- Christopher PeetzDirector
- Offering amount
- $91M
- Amount sold
- $91M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedAug 2020 · 25 investors · BiotechnologyRule 506(b)
▶$60MraisedAug 2020 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ConwayDirector
- Paul SekhriDirector
- Cui XiangminDirector
- James TopperDirector
- Jay VenkatesanDirector
- James Paul RickeyExecutive Officer
- Peter ThompsonDirector
- Mitchell GoldExecutive Officer, Director
- Stanford PengExecutive Officer
- Christopher PeetzDirector
- Offering amount
- $82.7M
- Amount sold
- $60M
- Sales commissions
- $3.3M
- Placement agents
- Oppenheimer & Co. Inc., Cowen and Company
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.3MraisedJan 2019 · 8 investors · BiotechnologyRule 506(b)
▶$25.3MraisedJan 2019 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay VenkatesanDirector
- James Paul RickeyExecutive Officer
- Mitchell GoldExecutive Officer, Director
- James TopperDirector
- Mark James LittonExecutive Officer
- Cui XiangminDirector
- Peter ThompsonDirector
- Christopher PeetzDirector
- Robert ConwayDirector
- Stanford PengExecutive Officer
- Paul SekhriDirector
- Offering amount
- $48.7M
- Amount sold
- $25.3M
- Sales commissions
- $907.5K
- Finders' fees
- $75K
- Placement agents
- Piper Jaffray & Co.
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$17MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stanford PangExecutive Officer
- Peter ThompsonDirector
- Mitchell H. GoldExecutive Officer, Director
- Jay VenkatesanExecutive Officer, Director
- J. Paul RickeyExecutive Officer
- James TopperDirector
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10.3MraisedJun 2016 · 3 investors · BiotechnologyRule 506(b)
▶$10.3MraisedJun 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan SwansonExecutive Officer
- Peter ThompsonDirector
- Mitchell H. GoldExecutive Officer, Director
- Jay VenkatesanExecutive Officer, Director
- James TopperDirector
- David MillerExecutive Officer
- Michael KornackerExecutive Officer
- Offering amount
- $48M
- Amount sold
- $10.3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.3MraisedMay 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Mitchell H GoldExecutive Officer, Director
- Michael KornackerExecutive Officer, Director
- Ryan SwansonExecutive Officer, Director
- David MillerExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$30MraisedNov 2014 · 12 investors · PharmaceuticalsRule 506(b)
▶$30MraisedNov 2014 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan LeffDirector
- Tom SokolowskiExecutive Officer
- Howard FurstDirector
- Evan LohDirector
- John MooreDirector
- Joseph LoscalzoDirector
- Offering amount
- $40M
- Amount sold
- $30M
- Finders' fees
- $845.6K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Alpine Immune Sciences went on to found or lead other companies.
Acquisitions · 1
Early investors' stakes continue via these dealsNivalis
Nivalis Therapeutics was a Boulder, Colorado clinical-stage biopharmaceutical company developing cavosonstat, an oral GSNOR inhibitor for cystic fibrosis, which failed its Phase 2 trial.
In the news
Frequently asked questions
- Who founded Alpine Immune Sciences?
- Alpine Immune Sciences was founded by Mitchell Gold in 2014.
- Who are Alpine Immune Sciences's investors?
- Alpine Immune Sciences's investors include Decheng Capital, Frazier Life Sciences, Biotechnology Value Fund, OrbiMed.
- How much funding has Alpine Immune Sciences raised?
- Alpine Immune Sciences has disclosed $234.9M raised across 7 rounds.
- Where is Alpine Immune Sciences headquartered?
- Alpine Immune Sciences is headquartered in Seattle, US.